Compare
Standard Biotools Inc. vs ARS Pharmaceuticals, Inc. vs Nurix Therapeutics, Inc. vs Cytokinetics Inc
| Latest fiscal year | Standard Biotools Inc. LAB | ARS Pharmaceuticals, Inc. SPRY | Nurix Therapeutics, Inc. NRIX | Cytokinetics Inc CYTK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-11-30 | 2025-12-31 |
| Revenue | $85.33M | $84.28M | $83.98M | $88.04M |
| Revenue growth (YoY) | -6.2% | -5.5% | +54.0% | +376.6% |
| Gross margin | 49.9% | n/a | n/a | n/a |
| Operating margin | -129.2% | -212.9% | -340.2% | -695.4% |
| Net margin | -87.8% | -203.3% | -314.9% | -891.6% |
| Net income | -$74.90M | -$171.30M | -$264.46M | -$784.96M |
| EPS (Diluted) | -$0.20 | -$1.74 | -$3.05 | -$6.54 |
| Operating cash flow | -$74.34M | -$170.87M | -$249.47M | -$510.01M |
| Free cash flow | -$82.65M | -$171.21M | -$263.47M | -$534.82M |
| Cash & equivalents | $120.86M | $41.32M | $246.96M | $122.52M |
| Total assets | $567.75M | $327.65M | $688.13M | $1.42B |
| Total liabilities | $143.46M | $213.39M | $149.39M | $2.08B |
| Shareholders' equity | $424.29M | $114.26M | $538.75M | -$659.62M |
| Return on year-end equity | -17.7% | -149.9% | -49.1% | n/a |
| Shares outstanding | 386.38M | 99.29M | 101.81M | 122.94M |
Revenue, most recent five fiscal years
| Fiscal year | Standard Biotools Inc. | ARS Pharmaceuticals, Inc. | Nurix Therapeutics, Inc. | Cytokinetics Inc |
|---|---|---|---|---|
| Latest | $85.33M Ended 2025-12-31 | $84.28M Ended 2025-12-31 | $83.98M Ended 2025-11-30 | $88.04M Ended 2025-12-31 |
| 1 year earlier | $91.01M Ended 2024-12-31 | $89.15M Ended 2024-12-31 | $54.55M Ended 2024-11-30 | $18.47M Ended 2024-12-31 |
| 2 years earlier | $106.34M Ended 2023-12-31 | $30.0K Ended 2023-12-31 | $76.99M Ended 2023-11-30 | $7.53M Ended 2023-12-31 |
| 3 years earlier | $97.95M Ended 2022-12-31 | $1.32M Ended 2022-12-31 | $38.63M Ended 2022-11-30 | $94.59M Ended 2022-12-31 |
| 4 years earlier | $130.58M Ended 2021-12-31 | $5.51M Ended 2021-12-31 | $29.75M Ended 2021-11-30 | $70.43M Ended 2021-12-31 |